View this email in your browser
TrialStat News for February 2020
Don't Miss the SCOPE Summit in Orlando, Florida on February 18th to the 21st!
Join us at the forefront of a new paradigm in life sciences technology, delivering integrated, flexible, and intuitive solutions that meet the needs of your clinical programs. Meet our team of experts and explore how tailored solutions will help you design novel clinical trials taking advantage of TrialStat’s integrated solutions, real world data, imaging & adjudication, and bespoke machine learning.

Attending SCOPE? Enter our draw for a Nespresso Vertuo & Aeroccino by downloading the Postcard and bringing it to the team at booth 701!

SCOPE Summit for Clinical Operations Executives - February 18th to 21st, 2020

Thank you from the entire TrialStat Team!

World first as drug developed using AI enters clinical trials

This may just be the first drug to be generated using artificial intelligence (AI) which has now entered clinical trials in Japan.

“The project has been particularly heralded for the speed it took to complete – taking just 12 months when compared to the typical five years it takes drug companies to complete the research phase. For instance, the candidate compound for the drug was found within 350 synthesised compounds, compared to the usual 2,500 compounds it takes drug companies to discover a novel compound.”

Continue Reading The Press Release

Microsoft takes the wraps off $40 million, five-year ‘AI for Health’ initiative

Microsoft has recently announced a $40 Million investment in AI for Health Initiatives.

“Through its AI for Good projects, Microsoft is applying lessons from software to artificial intelligence technologies that are under development. In the case of health, Microsoft officials said their mission is to use insights derived from AI technologies and techniques to search for cures for diseases that plague humanity.”

Continue Reading Article

A single number helps Stanford data scientists find most dangerous cancer cells

Biomedical data scientists at the Stanford University School of Medicine have shown that the number of genes a cell uses to make RNA is a reliable indicator of how developed the cell is, a finding that could make it easier to target cancer-causing genes.“

Continue Reading Article

Meet The TrialStat Team In Person

Book Your Personalized Demo Today!

To book your personalized demonstration of TrialStat's Unified eClinical Suite, please contact Christopher Kata at 905 999-1957 or by email at
A New Paradigm in Data Management Technology
Learn More About TrialStat
A New Paradigm In Data Management Technology
LinkedIn - TrialStat Solutions Inc.
Copyright © 2020 TrialStat Solutions Inc., All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.